Latest News
Isomorphic Labs Clinical Trial: When Will Its AI-Designed Drugs Start?
The first Isomorphic Labs clinical trial has no public start date as of 18 November 2026. In January, founder and chief executive Sir Demis Hassabis targeted first trials by the end of 2026. The company’s newest statement does not repeat that date. That statement came...
Latest News
Weaker or Just Lighter? The Measurement GLP-1 Weight Loss Is Missing
Body-composition scans report how much lean mass a patient loses on semaglutide or tirzepatide. They do not report whether the patient got weaker. That can be measured in about fifteen minutes. Ask a patient on a GLP-1 drug how treatment is going and you will hear a...
COINS Act Biotech Rule: Does It Cover China Licensing Deals?
Treasury’s own guidance says its proposed COINS Act biotech rule does not list a standalone licence as covered. The final text will decide. Treasury released the proposal on 22 October 2026, and it would add biotechnology to the US outbound investment programme. The...
Beyond Brain Organoids: What Makes a CNS Drug Screening Hit Credible?
Summary: Human iPSC-derived neurons and brain organoids are expanding opportunities for CNS drug screening. However, identifying a promising compound is only the beginning. Creative Biolabs highlights how disease-relevant neuronal models, multiparametric phenotypic...
OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares
How does OLN324 compare with Vabysmo? In the only head-to-head data found, it dried the retina faster in diabetic macular oedema. However, differences in durability and vision were small. That evidence comes from a 164-patient Phase 1b trial, and no Phase 3 comparison...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Ollin Biosciences Acquisition: What Is J&J Paying and What Does It Get?
Johnson & Johnson (J&J) will pay $2.2 billion upfront in the Ollin Biosciences acquisition. Up to about $1.125 billion more is payable in milestones. The deal brings OLN324, a bispecific antibody for wet age-related macular degeneration (AMD) and diabetic...
Why Biotechs Hire Quality and Regulatory Too Late, and What It Costs Them
In short: Most early-stage biotechs bring in their first permanent Quality or Regulatory hire later than they should, often only when an audit, a funding milestone or a submission is close. Hiring Quality and Regulatory people earlier costs less over time, makes...
Alzheimer’s Blood Tests: How Close Is Routine Screening?
For decades, confirming Alzheimer’s pathology meant an amyloid PET scan or a lumbar puncture. In 15 months, US regulators have cleared four blood tests that can do a similar job from a blood draw. Yet each Alzheimer’s blood test now on the US market is a diagnostic...
Deramiocel FDA Decision: Can Capricor Win Approval in Duchenne?
The deramiocel FDA decision is due by 22 November 2026. Deramiocel is Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy (DMD). The US Food and Drug Administration (FDA) has had a turbulent 16 months with it. A complete response letter (CRL) came in...
Ivonescimab FDA Approval: What the Complete Response Letter Means
The FDA has declined to approve ivonescimab for EGFR-mutated lung cancer, Summit Therapeutics said on Sunday 15 November 2026. The agency issued a complete response letter, so ivonescimab FDA approval is not in place in this setting. The goal date had been Saturday 14...
Environmental Cost of AI and ML in Life Science: Is It Bad for the Planet?
During a lab internship, I spent three months counting cells under a microscope. One slide at a time, one cell at a time. Today a trained model can do that counting in seconds, and that speed raises a question about the environmental cost of AI. That is the promise of...
Efficiency vs. Resilience: The Defining Life Sciences Battle of 2027
Tension is building in the life sciences industry as companies are asked to do more with less, while balancing efficiency and resilience. In the U.S., healthcare costs are rising faster than the economy, putting pressure on pricing and reimbursement [1]. Investors are...
Weekly News Roundup | 16 November 2026
Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...
Why Did Pelacarsen Fail? What Lp(a)HORIZON Means for Lp(a) Drugs
Why did pelacarsen fail, when the drug did exactly what it was designed to do? Novartis’s antisense therapy lowered lipoprotein(a), or Lp(a), by an estimated 77.7 percentage points more than placebo at one year. Yet heart attacks, strokes, urgent coronary procedures...
Home Pregnancy and Ovulation Tests: The Result Is Only Half the Job
Imagine someone using a home pregnancy test exactly as instructed. They take the sample, check the result within the stated time and see a negative result. But they tested before pregnancy hormone levels were high enough to detect. The test may have worked as...
Clinical Trial Results 13 November 2026
Clinical trial results 13 November 2026: obesity and cardiovascular risk, sleep apnoea, hepatitis delta, hidradenitis suppurativa, triglycerides and peanut allergy. Boehringer Ingelheim’s survodutide met its cardiovascular non-inferiority endpoint in obesity. Eli...
NICE Cost-Effectiveness Threshold: What Has Changed Six Months On?
The NICE cost-effectiveness threshold rose on 31 March 2026, the first increase in more than two decades. Six months on, early data suggest appraisal committees are using the wider range in full. Recommendation rates have risen, and fewer companies are walking away...
Ollin Biosciences Acquisition: What Is J&J Paying and What Does It Get?
Johnson & Johnson (J&J) will pay $2.2 billion upfront in the Ollin Biosciences acquisition. Up to about $1.125 billion more is payable in milestones. The deal brings OLN324, a bispecific antibody for wet age-related macular degeneration (AMD) and diabetic...
Why Biotechs Hire Quality and Regulatory Too Late, and What It Costs Them
In short: Most early-stage biotechs bring in their first permanent Quality or Regulatory hire later than they should, often only when an audit, a funding milestone or a submission is close. Hiring Quality and Regulatory people earlier costs less over time, makes...
Alzheimer’s Blood Tests: How Close Is Routine Screening?
For decades, confirming Alzheimer’s pathology meant an amyloid PET scan or a lumbar puncture. In 15 months, US regulators have cleared four blood tests that can do a similar job from a blood draw. Yet each Alzheimer’s blood test now on the US market is a diagnostic...
Deramiocel FDA Decision: Can Capricor Win Approval in Duchenne?
The deramiocel FDA decision is due by 22 November 2026. Deramiocel is Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy (DMD). The US Food and Drug Administration (FDA) has had a turbulent 16 months with it. A complete response letter (CRL) came in...
Ivonescimab FDA Approval: What the Complete Response Letter Means
The FDA has declined to approve ivonescimab for EGFR-mutated lung cancer, Summit Therapeutics said on Sunday 15 November 2026. The agency issued a complete response letter, so ivonescimab FDA approval is not in place in this setting. The goal date had been Saturday 14...
Environmental Cost of AI and ML in Life Science: Is It Bad for the Planet?
During a lab internship, I spent three months counting cells under a microscope. One slide at a time, one cell at a time. Today a trained model can do that counting in seconds, and that speed raises a question about the environmental cost of AI. That is the promise of...
Efficiency vs. Resilience: The Defining Life Sciences Battle of 2027
Tension is building in the life sciences industry as companies are asked to do more with less, while balancing efficiency and resilience. In the U.S., healthcare costs are rising faster than the economy, putting pressure on pricing and reimbursement [1]. Investors are...
Weekly News Roundup | 16 November 2026
Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...
Why Did Pelacarsen Fail? What Lp(a)HORIZON Means for Lp(a) Drugs
Why did pelacarsen fail, when the drug did exactly what it was designed to do? Novartis’s antisense therapy lowered lipoprotein(a), or Lp(a), by an estimated 77.7 percentage points more than placebo at one year. Yet heart attacks, strokes, urgent coronary procedures...
Home Pregnancy and Ovulation Tests: The Result Is Only Half the Job
Imagine someone using a home pregnancy test exactly as instructed. They take the sample, check the result within the stated time and see a negative result. But they tested before pregnancy hormone levels were high enough to detect. The test may have worked as...
Clinical Trial Results 13 November 2026
Clinical trial results 13 November 2026: obesity and cardiovascular risk, sleep apnoea, hepatitis delta, hidradenitis suppurativa, triglycerides and peanut allergy. Boehringer Ingelheim’s survodutide met its cardiovascular non-inferiority endpoint in obesity. Eli...
NICE Cost-Effectiveness Threshold: What Has Changed Six Months On?
The NICE cost-effectiveness threshold rose on 31 March 2026, the first increase in more than two decades. Six months on, early data suggest appraisal committees are using the wider range in full. Recommendation rates have risen, and fewer companies are walking away...
Featured Articles
Further News
Risto-cel Approval: When Could Beam’s Sickle Cell Therapy Reach Patients?
Beam Therapeutics plans to file for US risto-cel approval as early as year-end 2026. Under the FDA’s published review goals, a decision would follow roughly eight to 12 months after submission. No FDA action date has been announced. The plan follows positive topline...
argenx Unnatural Products Deal: What Does $550 Million Upfront Buy?
The argenx Unnatural Products deal buys a macrocyclic peptide discovery platform and its Santa Cruz research team. It also brings a portfolio of therapeutic macrocycles, none of which the companies have named. argenx will pay $550 million upfront in cash. Up to $595...
Beyond the Magic Marker: What EEG Could Add to ADHD Assessment
The search for a single brainwave test for ADHD has largely failed. But that was always the wrong goal. The more useful question is whether EEG, used alongside clinical assessment, could add information that helps make ADHD assessment more accurate and treatment more...
From GLP-1 Trial Results to the Follow-Up Visit
A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...
Biotech IPO Tracker 2026: How This Year’s Listings Have Traded
Biotech IPO tracker last updated: 10 November 2026. Prices as of the 6 November 2026 close. After a lean 2025, this year has reopened the US market for biotech flotations. This biotech IPO tracker lists every US-listed drug developer that has priced an initial public...
Creative Biolabs Helps Improve Reproducibility Across iPSC Organoid Studies
As iPSC-derived organoids gain importance in disease modeling and drug discovery, Creative Biolabs highlights iPSC differentiation consistency, cell characterization, and application-specific validation to help researchers develop more reliable experimental models....
Factor XIa Inhibitor Approved: How Asundexian Compares With Milvexian
The first factor XIa inhibitor approved in the US is Bayer’s asundexian, sold as Sunharbo. It cannot yet be compared directly with milvexian, the rival from Bristol Myers Squibb and Johnson & Johnson. No head-to-head trial exists, and milvexian’s stroke results...
Longevity Science Is Advancing. Can Clinical Care Keep Up?
The search to live longer is not new, but we are no longer looking for a hypothetical fountain of youth. Over the past few decades, research into metabolic health, longevity biomarkers, and more has led to longevity breakthroughs that open up new possibilities for...
Three Grant Budget Rules That Quietly Cost Life Science SMEs Money
Most biotech and medtech teams that lose grant money do not lose it by being ineligible. They lose it by putting a correct cost in the wrong line. The three grant budget rules below come up in almost every budget review: one from Horizon Europe, one from US federal...
GLP-1 Medications List: Every Approved GLP-1 Receptor Agonist Compared (2026)
Regulatory status checked on 11 November 2026. Seven molecules make up the approved GLP-1 class in the US, Europe and the UK. They differ in dosing, in whether they are injections or tablets, and in the conditions they treat. This GLP-1 medications list covers every...
What It Takes To Move Biomanufacturing Toward Commercial Scale
Scientific breakthroughs get attention for good reason. They are the moments when something that did not exist before suddenly becomes possible. But anyone who has spent time trying to commercialize biotechnology learns another lesson pretty quickly: proving that...
GLP-1 Vision Loss: What Does the FDA’s New NAION Warning Mean?
The FDA now requires every GLP-1 receptor agonist label to carry a warning about a rare eye condition. The condition is non-arteritic anterior ischaemic optic neuropathy, or NAION. The agency announced the change in a drug safety communication on 9 November 2026. For...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.













